Profile of HIV Type 1 coreceptor tropism among Kenyan patients from 2009 to 2010

Show simple item record

dc.contributor.author Ng'ang'a, Zipporah W.
dc.contributor.author Nyamache, Anthony K.
dc.contributor.author Muigai, Anne W.T.
dc.contributor.author Khamadi, Samoel A.
dc.date.accessioned 2014-12-03T06:08:37Z
dc.date.available 2014-12-03T06:08:37Z
dc.date.issued 2013
dc.identifier.citation AIDS Research and Human Retroviruses. August 2013, 29(8) en_US
dc.identifier.uri http://online.liebertpub.com/doi/abs/10.1089/aid.2012.0284
dc.identifier.uri http://hdl.handle.net/123456789/290
dc.description doi:10.1089/aid.2012.0284. en_US
dc.description.abstract A switch of HIV coreceptor usage from CCR5 to CXCR4 occurs in AIDS pathogenesis and may play a critical role in the use of entry inhibitors. To determine the potential usefulness of maraviroc and other CCR5 antagonists among drug-naive and experienced patients in Kenya, the env–C2-V3 gene was successfully sequenced in samples from 176 (98 men and 78 female) consenting subjects between January 2009 and December 2012. In silico CPSSM, webPSSM/, and (ds) Kernel tools were used in predicting coreceptor usage. On the basis of the env V3 loop sequences, 84.1% (148) were reported with R-5 tropism, 4.5% (5) were dual tropic, while 13.4% (23) were of X4 tropism. However, similar to previous studies conducted in Kenya on genetic diversity, HIV-1 subtype A1 (73.9%; 130/176) still remains the most dominant subtype. The high levels of R5 tropism among the studied Kenyan infected populations suggested the potential use of CCR5 antagonists as new therapeutic options in Kenya. en_US
dc.language.iso en en_US
dc.publisher Mary Ann Liebert, Inc. en_US
dc.title Profile of HIV Type 1 coreceptor tropism among Kenyan patients from 2009 to 2010 en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Dspace


Browse

My Account